
List of New Hepatitis C (Hep C) Drugs
Mavyret (glecaprevir and pibrentasvir); Manufactured by AbbVie and FDA approved in 2017.
Epclusa (sofosbuvir and velpatasvir); Manufactured by Gilead and FDA approved in 2016
Zepatier (elbasvir and grazoprevir); Manufactured by Merck and FDA approved in 2016
Daklinza (daclatasvir); Manufactured by Bristol-Myers Squibb and FDA approved in 2015.
Technivie (ombitasvir, paritaprevir, and ritonavir); Manufactured by AbbVie and FDA approved in 2015.
Harvoni (ledipasvir and sofosbuvir); Manufactured by Gilead and FDA approved in 2015
Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets); Manufactured by AbbVie and FDA approved in 2014.
Sovaldi (sofosbuvir); Manufactured by Gilead and FDA approved in 2014
Olysio (simeprevir); Manufactured by Janssen and FDA approved in 2013
Mechanisms of Action
These newer hepatitis c drugs work through inhibition of HCV NS3/4A protease or HCV NS5A/NS5B enzymes and some may be combined with a CYP3A4 inhibitor. HCV NS3/4A protease is an enzyme important for HCV replication and reproduction.
HCV NS5A and NS5B enzymes play a key role in HCV RNA replication and viral assembly. Replication is the process in which the virus uses the host’s cells mechanism to create more virus RNA. Viral assembly is putting that RNA into an actual virus structure which allows HCV to spread.
Some of these drugs may be combined with a CYP3A4 inhibitor, an enzyme involved in the metabolism of potentially toxic compounds, including drugs. Medications that inhibit CYP3A4 can increase the effects of medications that are broken down by these enzymes.
Hep C Drugs That Contain HCV NS3/4A Protease inhibitor
Hep C Drugs That Contain HCV NS5A protein inhibitor
Hep C Drugs That Contain HCV NS5B RNA Dependent RNA Polymerase Inhibitor
HCV Genotypes Treated By Each Medication
Currently, there are six genotypes of HCV. HCV medications are effective against specific genotypes. Genotype 1 is the most prevalent in the US.
There are two drugs that currently treat all six HCV genotypes.
Eight of the nine drugs are FDA approved for treatment of Genotype 1, which is the most prevalent in the US. These drugs include:
Four of the nine drugs are FDA approved to treat Genotype 3. These drugs include:
Seven of the nine drugs are FDA approved to treat Genotype 4. These drugs include:
Three of the nine drugs are FDA approved to treat Genotype 5. These drugs include:
Three of the nine drugs are FDA approved for treatment of Genotype 6. These drugs include:
Next: Cure Rates, Length of Treatment, Use with ribavirin, Cost,
Copyright 2023 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap